SLC6A4 Gene — Solute Carrier Family 6 Member 4
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A4 Gene — Serotonin Transporter</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC6A4 (SERT, 5HTT)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6532</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000108576</td>
</tr>
<tr>
<td class="label">Uniprot ID</td>
<td>P31645</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>630 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~70 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>SERT, 5HTT, SAT2, hSERT</td>
</tr>
<tr>
<td class="label">Step</td>
<td>Process</td>
</tr>
<tr>
<td class="label">1</td>
<td>Na+ binding to extracellular site</td>
</tr>
<tr>
<td class="label">2</td>
<td>Serotonin binding</td>
</tr>
<tr>
<td class="label">3</td>
<td>Cl- binding</td>
</tr>
<tr>
<td class="label">4</td>
<td>Conformational change</td>
</tr>
<tr>
<td class="label">5</td>
<td>Substrate release inside</td>
</tr>
<tr>
<td class="label">6</td>
<td>Return to outward-facing state</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Brand Names</td>
</tr>
<tr>
<td class="label">Fluoxetine</td>
<td>Prozac, Sarafem</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>Zoloft</td>
</tr>
<tr>
<td class="label">Paroxetine</td>
<td>Paxil</td>
</tr>
<tr>
<td class="label">Citalopram</td>
<td>Celexa</td>
</tr>
<tr>
<td class="label">Escitalopram</td>
<td>Lexapro</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">SLC6A3 (DAT)</td>
<td>Family member</td>
</tr>
<tr>
<td class="label">SLC6A2 (NET)</td>
<td>Family member</td>
</tr>
<tr>
<td class="label">TPH2</td>
<td>Enzyme</td>
</tr>
<tr>
<td class="label">MAOA</td>
<td>Enzyme</td>
</tr>
<tr>
<td class="label">HTR1A-HTR7</td>
<td>Receptors</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">ANXIETY</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">176 edges</a></td>
</tr>
</table>
Pathway Diagram
Mermaid diagram (expand to render)
SLC6A4 Gene — Solute Carrier Family 6 Member 4
Introduction
SLC6A4 (Solute Carrier Family 6 Member 4), also known as the serotonin transporter (SERT) or 5-HTT, is a membrane protein that mediates the reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft back into presynaptic neurons. This reuptake is the primary mechanism for terminating serotonin signaling, making SLC6A4 a critical regulator of serotonergic neurotransmission. The serotonin transporter serves as the principal regulator of serotonergic signaling duration and intensity, fundamentally influencing mood, cognition, sleep, and numerous other neurological processes. Notably, SLC6A4 has been increasingly implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, where serotonergic dysfunction contributes to disease progression and symptomology [@murphy2008].
The serotonin transporter represents one of the most extensively studied proteins in neuropsychopharmacology due to its central role in the mechanism of action of selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression and anxiety disorders. Understanding SLC6A4 structure, function, and regulation provides critical insights into both normal brain function and the pathophysiology of multiple neurological conditions.
Genomic Structure
The SLC6A4 gene is located on chromosome 17q11.2 and consists of 14 exons spanning approximately 40 kb. The gene encodes a protein of 630 amino acids with a molecular weight of approximately 70 kDa. The promoter region contains several regulatory elements including the well-characterized 5-HTTLPR polymorphism and additional variable number tandem repeat (VNTR) regions within intron 2 [@canli2006].
Regulatory Polymorphisms
5-HTTLPR (Serotonin-Transporter-Linked Polymorphic Region)
The most extensively studied polymorphism in SLC6A4 is a 5-HTTLPR located in the promoter region:
- Short (S) allele: 44 bp deletion, associated with reduced transcriptional efficiency (~30-40% lower expression)
- Long (L) allele: 44 bp insertion, associated with higher baseline expression
- L_A and L_G variants: The L allele has two sub-variants (L_A and L_G), where L_G shows similar activity to the S allele
This polymorphism has been extensively studied in relation to:
- Depression susceptibility and treatment response
- Anxiety disorders
- Stress vulnerability and resilience
- Neurodegenerative disease risk [@stocker2006]
- Neuroimaging phenotypes
STin2 VNTR
A variable number tandem repeat in intron 2 (STin2) containing 9, 10, or 12 copies of a 17-bp repeat:
- The 12-repeat allele associated with higher expression in some studies
- Implicated in various psychiatric conditions
- May interact with 5-HTTLPR
Protein Structure and Function
Structural Features
SLC6A4 is a member of the neurotransmitter sodium symporter (NSS) family (SLC6A), which includes transporters for dopamine (DAT/SLC6A3), norepinephrine (NET/SLC6A2), and GABA (GATs/SLC6A). The protein contains:
12 transmembrane domains: Alpha-helical segments that span the membrane, forming the translocation pathway
Intracellular N- and C-termini: Regulatory domains containing phosphorylation sites and protein interaction motifs
Extracellular loops: Contain glycosylation sites important for protein folding and trafficking
Binding sites: For serotonin, sodium ions, and chloride ionsTransport Mechanism
SLC6A4 operates as a secondary active transporter utilizing the sodium gradient:
Sodium coupling: Two Na+ ions co-transported with each serotonin molecule
Chloride dependence: One Cl- ion also required for transport
Electrogenic transport: Net positive charge moved into the cell (3 Na+ + 5-HT vs 1 Cl-)
Voltage dependence: Transport rate depends on membrane potentialSubstrate Specificity
SLC6A4 transports:
- Serotonin (5-hydroxytryptamine, 5-HT) — primary substrate, Km ~ 0.1-1 μM
- Tryptamine — lower affinity
- Some hallucinogenic compounds — partial substrates (e.g., MDMA)
- Amphetamine derivatives — some act as substrates, others as inhibitors
The transport mechanism involves alternating access:
Outward-facing state: Substrate binding site accessible to extracellular space
Occluded state: Substrate and ions bound, channel closed
Inward-facing state: Substrate release to intracellular space
Return step: Transporter returns to outward-facing stateThis cycle is driven by the electrochemical gradient for Na+ and can be inhibited by multiple compounds.
Regulation of SLC6A4
Transcriptional Regulation
Promoter activity: 5-HTTLPR genotype significantly affects promoter activity
Epigenetic modification: DNA methylation of promoter region correlates with gene expression
Activity-dependent regulation: Neuronal activity can modulate SLC6A4 expression
Hormonal regulation: Cortisol and other hormones affect transporter expressionPost-Translational Regulation
Phosphorylation: PKC-mediated phosphorylation reduces transport activity
Glycosylation: N-linked glycosylation required for proper membrane targeting
Palmitoylation: Affects membrane localization and function
Protein interactions: Interacts with scaffolding proteins (e.g., PSD-95, SNX27)Membrane Trafficking
- SLC6A4 is dynamically regulated by endocytosis and recycling
- Psychostimulants can cause internalization
- Agonist binding triggers regulatory internalization
Role in Neurodegenerative Diseases
Alzheimer's Disease
SLC6A4 has been implicated in Alzheimer's disease through several mechanisms [@stocker2006]:
Serotonergic dysfunction: AD is associated with reduced serotonergic signaling due to:
- Loss of serotonergic neurons in the raphe nuclei
- Reduced tryptophan availability
- Altered receptor and transporter expression
Amyloid interaction: Aβ peptides may affect SERT expression and function:
- Aβ can alter serotonin transporter phosphorylation
- May affect transporter trafficking to membrane
Neuroinflammation: Inflammatory processes modulate serotonin transporter:
- Cytokines can reduce SLC6A4 expression
- Neuroinflammation linked to depression in AD
Treatment target: SSRIs have been investigated for cognitive benefits in AD:
- May reduce amyloid burden
- Modulate neuroinflammation
- Improve behavioral and psychological symptoms
Depression comorbidity: High depression prevalence in AD patients linked to serotonergic changes:
- Bidirectional relationship between depression and AD risk
- 5-HTTLPR may modify AD risk in depressed patients
Parkinson's Disease
In Parkinson's disease, serotonergic dysfunction significantly impacts non-motor symptoms [@vermeulen2020]:
Depression in PD:
- SLC6A4 variants associated with depression in PD patients
- 5-HTTLPR may predict antidepressant response
- Serotonergic degeneration precedes dopaminergic loss in some cases
SSRI use in PD:
- SSRIs commonly used for depression in PD
- May affect levodopa efficacy through pharmacodynamic interactions
- Potential for serotonin syndrome with MAO-B inhibitors
Non-motor symptoms:
- Serotonergic dysfunction contributes to depression, anxiety, sleep disorders
- Olfactory dysfunction linked to serotonergic changes
- Fatigue may relate to transporter function
Locus coeruleus and raphe:
- Both noradrenergic and serotonergic systems affected in PD
- May explain comorbid depression and anxiety
- Lewy bodies found in serotonergic neurons
Other Neurodegenerative Conditions
- Migraine: Altered platelet SERT in some patients
- Epilepsy: Some evidence for SERT involvement
- Multiple sclerosis: Serotonergic changes reported
- Amyotrophic lateral sclerosis: Reduced serotonergic markers
- Huntington's disease: Serotonergic dysfunction prominent
Clinical Significance
SSRIs and Pharmacotherapy
SLC6A4 is the primary target of selective serotonin reuptake inhibitors (SSRIs), which block serotonin reuptake, increasing synaptic 5-HT levels:
Mechanism of Action
Acute effect: Blocking reuptake increases extracellular 5-HT
Downstream changes: Receptor desensitization over weeks
Neuroplasticity: Enhanced neurogenesis and synaptic plasticity
Delayed onset: Benefits typically take 2-4 weeksTherapeutic Implications
SSRI response: SLC6A4 genotype may predict treatment response
- L allele may show better response in some studies
- S allele associated with poorer response and treatment resistance
2.
Side effects:
- GI symptoms (initial)
- Sexual dysfunction (long-term)
- Insomnia
- Weight changes
3.
Discontinuation: Tapering required to avoid discontinuation syndrome
Treatment resistance: ~30-50% of patients do not respond adequatelyOther Target Drugs
- Serotonin-norepinephrine reuptake inhibitors (SNRIs): Venlafaxine, duloxetine
- Tricyclic antidepressants (TCAs): Some (e.g., clomipramine)
- Monoamine oxidase inhibitors (MAOIs): Indirect effects
Expression Patterns
Brain Expression
SLC6A4 is expressed in:
- Raphe nuclei: Primary site of serotonin neuron cell bodies in midbrain and brainstem
- Hippocampus: Modulates memory, emotion, and neuroplasticity
- Cortex: Involved in higher cognitive functions
- Basal ganglia: Motor and reward regulation
- Amygdala: Emotional processing and fear conditioning
- Thalamus: Sensory and regulatory functions
- Hypothalamus: Neuroendocrine regulation
Cell Type Expression
- Presynaptic serotonin neurons: Highest expression
- Astrocytes: Low expression
- Platelets: High SERT expression — used as peripheral model
- Enterochromaffin cells: Gut serotonin storage and release
- Lung: Minor expression
Species Differences
- Mouse SERT shows 92% homology to human
- Different 5-HTTLPR structure in rodents
- Expression patterns conserved across mammals
Molecular Pathways and Interactions
Signaling Interactions
GPCR interactions: Serotonin receptors modulate SERT function
Scaffold proteins: PSD-95, SNX27 regulate trafficking
Kinases: PKC, PKA, MAPK affect activity
Phosphatases: Calcineurin can dephosphorylate SERTResearch Directions
Current Understanding
- SLC6A4 is essential for serotonin homeostasis
- Genetic variants influence disease risk and treatment response
- SSRIs remain first-line depression treatment
- Role in neurodegeneration actively investigated
- PET ligands allow in vivo imaging of SERT
Knowledge Gaps
- Mechanisms of SSRI resistance
- Role in specific neurodegenerative processes
- Biomarker potential
- Real-world pharmacogenomics implementation
- Novel treatment approaches (rapid-acting antidepressants)
Key Publications
[Murphy DL, et al. (2008) Serotonin transporter: gene, gene boundaries, and haplotypes. Cell Mol Neurobiol 28:299-330](https://pubmed.ncbi.nlm.nih.gov/18215985/)
[Lesch KP, et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531](https://pubmed.ncbi.nlm.nih.gov/8758948/)
[Canli T, Lesch KP. (2006) Serotonin transporter gene and stress: a tale of two promoters. Neuropsychopharmacology 31:288-294](https://pubmed.ncbi.nlm.nih.gov/16319898/)
[Stocker CJ, et al. (2006) Serotonin transporter gene polymorphism and Alzheimer's disease. J Neurol Neurosurg Psychiatry 77:688-690](https://pubmed.ncbi.nlm.nih.gov/16484651/)
[Vermeulen E, et al. (2020) Serotonergic dysfunction in Parkinson's disease: a systematic review. J Parkinsons Dis 10:1645-1658](https://pubmed.ncbi.nlm.nih.gov/33280117/)
[Hauser RA, et al. (2021) Serotonin and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 82:29-35](https://pubmed.ncbi.nlm.nih.gov/33419653/)
[Blier P, El Mansari M. (2008) Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 363:2563-2575](https://pubmed.ncbi.nlm.nih.gov/18801849/)
[Kahn RS, et al. (2008) Serotonin transporter polymorphisms and sustained response to antidepressants. J Clin Psychopharmacol 28:497-501](https://pubmed.ncbi.nlm.nih.gov/18520979/)
[Rudolph LM, et al. (2023) Serotonin in neurodevelopment and neuropsychiatric disease. Neuroscience 519:1-24](https://pubmed.ncbi.nlm.nih.gov/37276028/)
[Ressler KJ, Nemeroff CB. (2012) Role of serotonergic system in the pathophysiology of depression and anxiety disorders. Depress Anxiety 29:460-468](https://pubmed.ncbi.nlm.nih.gov/21538641/)See Also
- [Serotonin](/proteins/serotonin)
- [Depression](/diseases/major-depressive-disorder)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [SSRIs](/therapeutics/ssris)
- [Raphe Nuclei](/cell-types/raphe-nuclei)
- [Neurotransmitter Transporters](/mechanisms/neurotransmitter-transporters)
External Links
- [NCBI Gene: SLC6A4](https://www.ncbi.nlm.nih.gov/gene/6532)
- [UniProt: P31645](https://www.uniprot.org/uniprot/P31645)
- [Ensembl: ENSG00000108576](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108576)
- [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000108576-SLC6A4)
Pathway Diagram
The following diagram shows the key molecular relationships involving SLC6A4 Gene — Serotonin Transporter discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)